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Abstract
Development of an effective treatment against advanced tumors remains a major challenge for 
cancer immunotherapy. We have previously developed a potent mannose-modified lipid calcium 
phosphate (LCP) nanoparticle (NP)-based Trp2 vaccine for melanoma therapy, but because this 
vaccine can induce a potent anti-tumor immune response only during the early stages of 
melanoma, poor tumor growth inhibition has been observed in more advanced melanoma models, 
likely due to the development of an immune-suppressive tumor microenvironment (TME). To 
effectively treat this aggressive tumor, a multi-target receptor tyrosine kinase inhibitor, sunitinib 
base, was efficiently encapsulated into a targeted polymeric micelle nano-delivery system 
(SUNb-PM), working in a synergistic manner with vaccine therapy in an advanced mouse 
melanoma model. SUNb-PM not only increased cytotoxic T-cell infiltration and decreased the 
number and percentage of MDSCs and Tregs in the TME, but also induced a shift in cytokine 
expression from Th2 to Th1 type while remodeling the tumor-associated fibroblasts, collagen, and 
blood vessels in the tumor. Additionally, inhibition of the Stat3 and AKT signaling pathways by 
SUNb-PM may induce tumor cell apoptosis or decrease tumor immune evasion. Our findings 
indicated that targeted delivery of a tyrosine kinase inhibitor to tumors can be used in a novel 
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synergistic way to enhance the therapeutic efficacy of existing immune-based therapies for 
advanced melanoma.
Graphical abstract
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1. Introduction
Immunotherapy holds much promise for the treatment of cancer [1–3]. A wide variety of 
approaches have been implemented in order to stimulate a range of innate and adaptive 
immune activities [4]. Strategies include the use of immunomodulatory antibodies, vaccines, 
and adoptive cell transfer [5–7]; however, most immunotherapeutic approaches on their own 
fall short of initial expectation when used against advanced malignancy [8]. Reasons for this 
limited success might be the immune-suppressive tumor microenvironment (TME) that 
presents in later tumor grades [9, 10]. Tumors are not just a mass of proliferating genetically 
abnormal cells; they are now well defined as a heterogeneous and structurally complex 
tissue. Malignant tumor cells can recruit a variety of cell types, including fibroblasts, 
immune inflammatory cells, and endothelial cells, through production and secretion of 
stimulatory growth factors and cytokines [11, 12]. This assortment of cells and molecules 
together comprises the TME. Antitumor immunity within the TME can be suppressed not 
only by tumor infiltrating leukocytes but also by tumor cells themselves through a number of 
mechanisms such as secretion of cytokines, expression of inhibitory receptors, or blockage 
of T cell function [13]. Many of these regulatory mechanisms can occur concurrently within 
the TME, resulting in multiple redundant levels of immune suppression, which reduces the 
effectiveness of immunotherapy. Therefore, development of an effective treatment against 
advanced tumors remains a major challenge for cancer immunotherapy.
The TME can impede immunotherapy, and approaches to specifically reduce immune 
suppression within the TME might be effective means to solve this problem. Sunitinib 
malate, an oral multi-target receptor tyrosine kinase inhibitor (TKI), has been approved by 
the Food and Drug Administration as a first line therapy for patients with metastatic renal 
cell cancer and proto-oncogene c-kit+ gastrointestinal stromal tumors [14]. Sunitinib has 
been shown to have a direct inhibitory effect on tumor growth by promoting tumor apoptosis 
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and inhibiting the tumor-promoting effect of vascular endothelial growth factor (VEGF) [15, 
16]. In addition, sunitinib can indirectly inhibit tumor growth by stimulating anti-tumor 
immune responses [17–19]. Based on its well documented tumor apoptosis and immune 
adjuvant properties, as well as the over-expressed sigma receptors on the surface of 
melanoma cells, we hypothesize that targeted delivery of hydrophobic sunitinib base to the 
tumor using anisamide-modified poly-lactic-glycolic-acid-poly (ethylene glycol) (PLGA-
PEG-MBA) polymeric micelles (PM) will result in a modulation of the TME and enhance 
the activity of vaccination against advanced tumors.
In our previous studies, we have successfully developed a potent mannose-modified lipid 
calcium phosphate (LCP) nanoparticle (NP)-based vaccine containing both tumor-specific 
antigen (tyrosinase-related protein 2 (Trp2) peptide) and adjuvant (CpG) to activate a 
mouse’s dendritic cells [20, 21]. Results showed that the LCP-Trp2 vaccination could 
generate a strong in vivo cytotoxic T lymphocyte (CTL) response, which resulted in a potent 
anti-tumor immune response against the Trp2-expressing melanoma. Previous studies have 
also indicated that immunotherapy effectively inhibits tumor progression in a B16F10 
melanoma model in the early stages of tumor progression (4 days after tumor inoculation). 
Unfortunately, vaccination with LCP-Trp2 at a later stage of tumor growth (13 days after 
tumor inoculation) is not very effective in inhibiting tumor growth, despite the fact that the 
systemic CTL response was the same [20]. Most likely, the immunotherapeutic efficiency 
was compromised because of increased immune suppression in the TME and faster tumor 
growth. Therefore, in the present study, a novel combined treatment was developed using 
intravenous delivery of sunitinib base in PLGA-PEG-MBA (SUNb-PM) and subcutaneous 
delivery of the LCP-Trp2 vaccine to treat the advanced melanoma. We expected that the 
tumor-targeted sunitinib base could specifically modulate the TME and reverse its immune 
suppression, increasing the anti-tumor immune response of the vaccine and inhibiting 
growth of the late-stage tumor (Scheme 1).
2. Materials & Methods
2.1. Materials
Sunitinib base was purchased from Selleckchem (Houston, TX, USA). Sunitinib malate was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). [3H]sunitinib TFA salt was purchased 
from ViTrax (20 Ci/mmol) (Placentia, CA, USA). Acid-terminated PLGA (lactide/glycolide 
(50:50)) was purchased from DURECT (Pelham, AL, USA). mPEG3500-NH2·HCl and 
tBOC-PEG3500-NH2·HCl were ordered from JenKem Technology USA, Inc. (Allen, TX). 
MBA was purchased from Sigma-Aldrich (St. Louis, MO, USA). PLGA-PEG and PLGA-
PEG-MBA were synthesized according to our previous publications and the structures were 
confirmed using 1H NMR [22].1,2-Dioleoyl-3-trimethylammonium-propane chloride salt 
(DOTAP), 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethyleneglycol-2000)] ammonium salt (DSPE-PEG) and 
dioleoylphosphatydic acid (DOPA) were purchased from Avanti Polar Lipids (Alabaster, 
AL, USA). Cholesterol was purchased from Sigma-Aldrich (St. Louis, MO, USA). DSPE-
PEG-Mannose was synthesized in our laboratory using DEPE-PEG-NHS (NOF, Shibuya-ku, 
Tokyo) and 4-Amino phenyl α-D-mannopyranoside (Sigma-Aldrich, St. Louis, MO) as 
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previously reported and the structure was confirmed using 1H NMR[21]. H-2Kb-restricted 
peptides Trp2 (SVYDFFVWL, MW1175), OVA (SIINFEKL, MW1773) and modified Trp2 
peptide, p-Trp2 (pSpSSSVYDFFVWL, MW1626) were purchased from Peptide 2.0 
(Chantilly, VA, USA). CpG ODN 1826 (5′-TCCATGACGTTCCTGACGTT-3′) was 
obtained from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals were purchased 
from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Animals and tumor cell lines
Female C57BL/6 mice aged 6 to 8 weeks were purchased from the National Cancer Institute 
(Bethesda, MD). All animal procedures were carried out under protocols approved by the 
Institutional Animal Care and Use Committees at the University of North Carolina at Chapel 
Hill. Murine B16F10 melanoma cell lines syngeneic with C57BL/6 mice were obtained 
from American Type Culture Collection (ATCC) and cultured with DMEM supplemented 
with 10% fetal bovine serum, 100 U/mL penicillin and 100 μg/mL streptomycin (Invitrogen, 
Carlsbad, CA) at 37 °C and 5% CO2.
2.3. Preparation of LCP-Trp2 vaccine
The LCP-based vaccine was prepared by a water-in-oil micro-emulsion technique as 
previously described [21]. Briefly, 600 μL CaCl2 (2.5M) containing the phosphorylated Trp2 
peptide and CpG ODN was dispersed in a 20 mL Cyclohexane/Igepal CO-520 (71:29, v/v) 
solution to form a well-dispersed Ca phase. Concurrently, 600 μL Na2HPO4 (12.5 mM, 
pH9.0) and 200 μL DOPA (20 mM) were dispersed in another 20 mL oil phase to obtain the 
phosphate phase. After the above micro-emulsion phases were stirred separately for 15 min, 
they were mixed together and stirred for another 30 min. Forty mL of ethanol was then 
added to break the micro-emulsion, and the calcium phosphate cores were collected by 
centrifugation (10,000 g× 20 min) and washed with ethanol 3 times. The pellets were 
dissolved in chloroform and mixed with 100 μL DOTAP (20 mM), 100 μL cholesterol (20 
mM), 20 μL DSPE-PEG-2000 (20 mM), and 20 μL DSPE-PEG-mannose (20 mM). After 
evaporating the chloroform, the LCP vaccine particles were dispersed in 100 μL of 5% 
glucose. The morphologies of LCP NPs were observed by transmission electron microscopy 
(TEM) (JEOL 100CX II TEM, JEOL, Japan). Particle size and zeta potential were measured 
by a Malvern Zetasizer Nano ZS (Malvern, Worcestershire, UK).
2.4. Preparation and characterization of sunitinib base-loaded PLGA-PEG-MBA polymeric 
micelles (SUNb-PM)
The solvent displacement method was employed to form the drug-loaded micelles [22]. 
Briefly, 0.7 mg of sunitinib malate or its free base and four mg of polymers (weight ratio of 
PLGA/PLGA-PEG/PLGA-PEG-MBA was fixed at 1:8:1) were dissolved in organic solvents 
(DMSO or THF). Micelles were formed by adding the drug-polymer solution dropwise into 
four mL of water under stirring at room temperature. The resulting suspension was allowed 
to stir uncovered for six h at room temperature to evaporate the organic solvent. The 
unencapsulated drug was removed by ultrafiltration (50,000 nominal molecular weight limit 
(NMWL), Millipore, Billerica, MA) at 4,000 g for 15 min. The drug-loaded micelles were 
then re-suspended, washed with water and stored in 5% glucose. The drug-loaded micelles 
were observed by TEM and particle size distributions/zeta potentials were determined using 
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a Malvern Zetasizer Nano ZS. Drug loading was measured using a UV spectrophotometer 
(Beckman Coulter, Atlanta, GA). Encapsulation efficiency (EE) and drug loading (DL) were 
calculated according to the formulas:
Stability was evaluated by determining the particle size and drug content during storage at 
4 °C
2.5. In vitro release of sunitinib base from SUNb-PM
In vitro release rates of sunitinib base from SUNb-PM in pH 7.4 or 5.8 were evaluated using a 
dialysis method. In order to establish a sink condition, 0.1% Tween-80 was added in the 
PBS. SUNb-PM with a final concentration of 300 μg/mL was placed into a dialysis tube with 
a molecular weight cut-off of 10,000 Da and dialyzed against 40 mL PBS in a thermo-
controlled shaker with a stirring speed of 100 rpm at 37 °C. An aliquot (2 mL) was drawn at 
predetermined time intervals, and fresh release medium (2 mL, 37°C) was added. The 
content of original sunitinib base in the release medium was determined using Agilent 1260 
HPLC equipped with a LIChrospherTM C18 column (particle size, 5 μm; 250 mm × 4.6 
mm). The mobile phase and gradient elution method were shown in Table S1. The flow rate 
was 1.0 mL/min. The detection wavelength was 268 nm, sample injection volume was 20 
μL, and the column temperature was 35 °C. The cumulative release amount at each time 
point was calculated from the percentage of the total solution that was taken in the aliquot (n 
= 6). Due to the degradation of the drug in release media (Figure S1), the release study was 
conducted only to 24 h to compare the release behavior of sunitinib base from micelles at 
different pH environments.
2.6. In vitro cytotoxicity studies
The in vitro cytotoxicity of sunitinib malate or SUNb-PM against the B16F10 cells was 
evaluated by the MTT assay. The free sunitinib malate solution was prepared by dissolving 
12 mg of sunitinib malate in 1.0 mL DMSO. The samples containing the drugs were diluted 
with culture medium to obtain the desired sunitinib concentration, ranging from 1.25 to 60 
μM. The B16F10 cell suspension in culture medium (DMEM+10% FBS) was seeded in 96-
well plates at 4×103 cells/well and was incubated at 37 °C in a humidified atmosphere with 
5 % CO2 for 24 h. The cells were then treated with either SUNb-PM micelles or sunitinib 
malate solution. After incubation for 24 h, the MTT cell viability assay was performed as 
described previously [23].
2.7. Tumor targeting of [3H]SUNb-PM in C57BL/6 mice bearing B16F10 tumors
Solid melanoma tumors were developed in C57BL/6 mice by subcutaneous inoculation of 
2×105 B16F10 cells into the right flank of the mice. When the tumors grew to approximately 
300 mm3, tumor-bearing mice were treated i.v. with a single dose of 10 mg/kg SUNb-PM 
containing 3H-labeled sunitinib base (TFA salt was neutralized by triethylamine) or treated 
p.o. with a single dose of 30 mg/kg SUNOS containing 3H-labeled sunitinib TFA salt. In 
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both the i.v. and p.o. groups, the dose of 3H-labeled sunitinib was fixed at 50 μCi/kg. The 
mice were sacrificed six h, 12 h, and 24 h post-i.v. or p.o. administration. Tumor tissue 
samples were first digested by Tissue Solubilizer (Amersham Biosciences Corp. NJ, USA) 
overnight at room temperature and then added to four mL of scintillation cocktail (Thermo 
Fisher Scientific Inc., MA, USA). The samples were then assayed using a liquid scintillation 
counter (Beckman coulter LS6500). The percentage of the administrated dose (% ID) in the 
tissue was calculated and normalized to the total weight of each organ. All tests were done 
in triplicate.
2.8. Tumor growth inhibition
To assay whether SUNb-PM has improved therapeutic efficacy in vivo when used in 
combination with the Trp2 vaccine, a subcutaneous tumor was established by inoculating 
2×105 B16F10 cells into the right flank of C57BL/6 mice. Sunitinib oral suspension 
(SUNOS) was used as a control. SUNOS was prepared according to a previous report, with 
slight modifications [24]. Briefly, sunitinib malate was directly suspended in a 
carboxymethylcellulose (CMC) solution (CMC 0.5 %, NaCl 1.8 %, and Tween 80 0.4 % in 
distillated water) with grinding. The final drug concentration in suspension was 3 mg/mL. 
When tumors grew to approximately 200 mm3 (day 13), mice were randomly divided into 
six groups receiving different treatments as follows: (i) normal PBS (the control group, 
n=6); (ii) LCP-Trp2 vaccine at 200 μg Trp2/kg (n=6); (iii) SUNOS at 30 mg/kg sunitinib 
malate (n=6); (iv) LCP-Trp2 vaccine at 200 μg Trp2/kg plus SUNOS at 30 mg sunitinib 
malate/kg (n=6); (v) SUNb-PM at 10 mg sunitinib base/kg (n=6); (vi) LCP-Trp2 vaccine at 
200 μg Trp2/kg plus SUNb-PM at 10 mg sunitinib base/kg. For the vaccine only and 
combination therapy groups, the vaccine was s.c. injected into the left flank of mice on day 
14. Sunitinib was administered p.o. or i.v. every other day for three total administrations 
starting on day 14. The tumor volumes were measured every day and calculated as A×B2/2, 
where A was the largest diameter and B was the smallest. After completion of the 
therapeutic experiment on day 19, mice were humanely sacrificed and tumor tissue and 
major organs were collected for further experiments. The tumors were weighed and the 
inhibition ratio (IR) was defined as IR (%) = [(Wc − Wt)/Wc]× 100, where Wc and Wt are 
the average tumor weights for the control group and each treatment group, respectively.
To further evaluate the antitumor effect of V+SUNb-PM formulations on the animals, the 
tumors were fixed with 4 % (v/v) paraformaldehyde in PBS (pH 7.4) and sectioned into 5 
μm slices. Apoptotic and non-apoptotic cells in tumor tissues were histologically evaluated 
with hematoxylin and eosin (H&E) staining and with the terminal 
deoxynucleotidyltransferase-mediated nick end labeling (TUNEL) assay, using a 
commercial apoptosis detection kit (Promega, Madison, WI). TUNEL-positive (apoptotic) 
cells had pyknotic nuclei with dark green fluorescent staining. Images of the sections were 
taken by a fluorescence microscope (Nikon, Tokyo, Japan). The apoptotic index was 
calculated by dividing the number of TUNEL-positive cells by the total number of cells in 
the field. Three randomly selected microscopic fields were quantitatively analyzed on 
ImageJ software.
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2.9. Safety evaluation
To monitor the potential toxicity of the above regimens, we monitored animal behavior and 
relative weight loss throughout the in vivo therapeutic experiment. After the tumor growth 
inhibition study (section 2.8), blood samples and major organs were collected. Several 
biological markers for liver/kidney function were measured from the blood samples: alanine 
transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), blood urea 
nitrogen (BUN) and serum creatinine (Scr). The organs were fixed with 4% (v/v) 
paraformaldehyde in PBS (pH 7.4), embedded in paraffin, and sectioned into 5 μm slices. 
Each section was processed for H&E staining and examined by a board certified veterinary 
pathologist.
2.10. Flow cytometric evaluation of single-cell suspensions
Tumor-infiltrating and splenic lymphocytes were analyzed by flow cytometry. In brief, 
tumor and spleen tissues were harvested and digested with collagenase A and hyaluronidase 
at 37 °C for 40 min. After lysis of the red blood cells (RBCs), the dissociated cells were 
dispersed with 1 mL of HBSS. For intracellular cytokine staining, the cells from the tumor 
and spleen tissue were permeabilized with 0.1% triton X-100 for 15 min. The density of 
total cells was 5×106/mL. The tumor infiltrating immune cells were stained with the 
following fluorescence-labeled antibodies: FITC-conjugated anti-mouse CD8a, FITC-
conjugated anti-mouse CD4, PE-conjugated anti-mouse Foxp3, FITC-conjugated anti-mouse 
CD11b, and PE-conjugated anti-mouse Gr-1 (BD, New South Wales, Australia). Flow 
cytometry was performed in quintuplicate for each group. Analysis was performed on a 
FACSCalibur flow cytometer and analyzed using Cell Quest software (BD Biosciences, San 
Jose, CA).
2.11. Immunofluorescence
Tissue section slides were processed via deparaffinization, antigen retrieval, 
permeabilization, and blocking with 1% bovine serum albumin (BSA) at room temperature 
for 1 h. MDSCs were defined using FITC-conjugated rat-anti-mouse CD11b and PE-
conjugated rat-anti-mouse Gr1 (BD, New South Wales, Australia). Tregs were defined using 
FITC-conjugated rat-anti-mouse CD4 and PE-conjugated rat-anti-mouse Foxp3 (BD, New 
South Wales, Australia). T cells were defined using FITC-conjugated rat-anti-mouse CD8a 
(BD, New South Wales, Australia). Vessels and tumor-associated fibroblasts (TAF) were 
characterized by rabbit-anti-mouse CD31 and rabbit-anti-mouse α-SMA, and then treated 
with Alexa Fluor647-conjugated goat-anti-rabbit antibody. Nuclei were counterstained with 
DAPI (Vector Laboratories Inc, Burlingame, CA). All commercial binding reagents were 
diluted according to the manufacturer’s recommendation. Images were taken using 
fluorescence microscopy (Nikon, Tokyo, Japan). Three randomly selected microscopic fields 
were quantitatively analyzed on ImageJ software.
2.12. Quantitative real-time PCR assay
Total RNA was extracted from tissue samples using an RNeasy kit (Qiagen, Valencia, CA) 
and cDNA was reverse-transcribed by a SuperScript First-Strand Synthesis System for RT-
PCR (Invitrogen, Grand Island, NY). Amplification was conducted using the SSO Advanced 
Huo et al. Page 7
J Control Release. Author manuscript; available in PMC 2018 January 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Universal Probe Supermix (Bio-rad, Hercules, CA), mouse-specific primers, and 100 ng of 
cDNA. Primers for mouse TGF-β, IL6, TNF-α, CCL2, IFN-γ, IL10, IL12a and IL2 were 
purchased from Life Technologies (Grand Island, NY). Mouse GAPDH primers were used 
as an endogenous control. The RT-PCR was performed in quintuplicate for each group. The 
reactions were conducted using a 7500 Real-Time PCR System, and the data were analyzed 
with the 7500 Software.
2.13. Masson trichrome staining
The Masson Trichrome assay was carried out to detect collagen in tumor tissues. Paraffin-
embedded tumor sections were deparaffinized and rehydrated. The slides were then stained 
using a Masson Trichrome kit (Saint Louis, MO, USA) according to the manufacturer’s 
instructions. Images were taken using light microscopy (Nikon, Tokyo, Japan). Three 
randomly selected microscopic fields were quantitatively analyzed on ImageJ software.
2.14. Change of tumor permeability
After a treatment schedule consistent with the tumor growth inhibition study (section 2.8), 
mice were i.v. injected with PLGA-PEG-MBA that was labeled with the lipophilic dye 1,1′-
dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) at a dose of 0.5 mg/kg 
and were sacrificed 24 h post administration. Tumor tissue was harvested and stained with a 
fluorescein-conjugated CD11b antibody (BD Biosciences, San Jose, CA). Images were 
taken using fluorescence microscopy (Nikon, Tokyo, Japan). Three randomly selected 
microscopic fields were quantitatively analyzed on ImageJ software.
2.15. Western blot analysis
Western blots were performed on lysates generated from single-cell suspensions from 
tumors after different treatments as previously described. Primary antibodies were directed 
against p-stat3, stat3, p-AKT, and AKT (all from Cell Signaling, Beverly, MA) and GAPDH 
(Santa Cruz biotechnology, Dallas, TX). After washed blots were incubated with horseradish 
peroxidase (HRP)-conjugated secondary antibodies (Abcam, Cambridge, MA), signals were 
detected using the Pierce ECL Western Blotting Substrate (Thermo, Rockford, IL). Western 
blot was performed in triplicate for each group and the optical density of each protein band 
was analyzed with ImageJ software.
2.16. In vivo CTL response
The in vivo CTL assay was performed according to a previously described protocol [20]. In 
brief, splenocytes from naïve C57BL/6 mice were collected and pulsed with 10 μM Trp2 or 
Ova control peptides in complete media at 37°C for one h. Both pulsed cell populations 
were then stained with 2 μM PKH-26 (Sigma-Aldrich, St. Louis, MO) following the 
manufacturer’s protocol. The Trp2 peptide-pulsed and Ova peptide-pulsed cells were then 
labeled with 4 μM and 0.4 μM carboxyfluorescein succinimidyl ester (CFSE), respectively. 
Eighteen C57BL/6 mice were divided into six groups and treated according to the schedule 
in section 2.8. Equal amounts of CFSEhigh (Trp2-pulsed cells) and CFSElow (Ova-pulsed 
cells) were mixed and i.v. injected into the treated mice. 18 h later, splenocytes were 
collected from these treated mice and subjected to flow cytometric analysis. The number of 
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CFSEhigh and CFSElow cells was calculated and the in vivo Trp2-specific lysis percentage 
was enumerated according to a published equation [20], also shown below. The in vivo CTL 
was performed in triplicate for each group.
2.17. Statistical Analysis
Statistical analysis was performed by a Student’s t test when comparing two groups, and by 
one-way ANOVA when comparing multiple groups. All results were expressed as mean ± 
S.D. unless otherwise noted. p<0.05 was considered statistically significant.
3. Results and Discussions
3.1. Preparation and characterization of SUNb-PM
Polymeric micelle-based drug delivery systems are a powerful approach to deliver water-
insoluble therapeutics to the tumor. Sigma receptors are well-known membrane-bound 
proteins that show high affinity for neuroleptics and are overexpressed on many human 
tumors including melanoma [25]. Therefore, MBA, an analog of anisamide and an agonist of 
sigma receptors, was used as a targeting ligand to further enhance the delivery of drugs to 
tumors. In this study, we encapsulated sunitinib into targeted PLGA-PEG-MBA micelles so 
that high bioavailability could be achieved in the tumor after systemic administration.
The physical entrapment of sunitinib into PLGA-PEG-MBA micelles was achieved by a 
well-established solvent displacement method [22]. The active ingredient in the commercial 
product Sutent® is the malate salt of sunitinib, which has a solubility in pure water of 
around 1 mg/mL [26]. The malate salt is used to increase the hydrophilicity of the drug for 
clinical use, which makes it much more difficult to load into the hydrophobic core of 
micelles. Although we found no papers on the preparation of nanoformulations containing 
sunitinib, the patents US 20120195826 A1 and WO 2014043625 A1 reported sunitinib 
malate nano-preparations based on PLGA-PEG or PLA-PEG micelles. Their studies showed 
a rather low drug loading content of less than 1 %. We also determined the loading amount 
and efficiency of Sunitinib malate into PLGA-PEG-MBA micelles. Not surprisingly, a low 
loading amount and encapsulation efficiency was obtained (5.1 % and 30.5 %, respectively) 
(Table 1).
Sunitinib base is more amenable to micellar encapsulation because its solubility in water is 
only ~1 % of that of sunitinib malate (4–8 μg/mL). Therefore, in the present study, sunitinib 
base was chosen as the therapeutic agent with which to prepare the drug-loaded micelles. 
Both DMSO and THF can dissolve the polymer and the drug, but it was found that using 
THF resulted in much higher drug loading and encapsulation efficiency than DMSO (Table 
1, drug loading 14.2 % vs. 2.1 %; encapsulation efficiency 94.3 % vs. 12.1 %). This may 
occur because sunitinib base exhibits extremely high solubility in DMSO (> 40 mg/mL), and 
the strong interaction between DMSO molecules and drug molecules hampers the drug from 
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partitioning into the micelles. In contrast, sunitinib base exhibits only a moderate solubility 
in THF (~5 mg/mL), which is enough to dissolve the drug while still allowing the drug to 
associate highly with the polymer.
The particle size of SUNb-PM as measured by dynamic light scattering technology was 
around 73 nm (Table 1), suggesting that polymeric micelles should be able to selectively and 
efficiently accumulate in the tumor by means of the tumor’s enhanced vessel permeability 
and decreased lymphatic drainage, termed the EPR effect [27]. Moreover, the particle size of 
SUNb-PM was much larger than blank micelles (73 nm vs 30 nm), indicating that the drug 
was actually loaded into the hydrophobic core of the micelles. The zeta potential of the drug-
loaded micelles was around + 4 mV, which is similar to the zeta potential of the blank 
micelles.
TEM was also used to visualize the size and morphology of SUNb-PM. As shown in Fig. 1B, 
SUNb-PM exhibited a spherical morphology with smooth surfaces. The observed micellar 
size was approximately 40–70 nm, which was slightly smaller than the hydrodynamic 
diameter obtained from the DLS experiment.
Most polymer micelles have poor physical stability after drug loading. In general, the 
stability of polymer micellar systems decreases as drug loading increases. PLGA-PEG-MBA 
micelles were found to possess an extremely high drug loading capacity for sunitinib base, 
and therefore it was necessary to further investigate its in vitro stability. Fig. 1C shows that 
the drug-loaded PLGA-PEG-MBA micellar solution could be stored at 4 °C for at least 4 
months without a significant change in particle size and drug content, indicating excellent 
stability in vitro.
The in vitro release behaviors of sunitinib base from SUNb-PM in two different buffer 
solutions (pH 7.4 and 5.8) were studied and are shown in Fig. 1D. Sunitinib base releases 
from micelles much more slowly at pH 7.4 than at pH 5.8, likely because of the re-
protonation of the amino group of sunitinib base at lower pH, which increases its ability to 
partition into water. This pH-dependent releasing behavior is of particular importance 
because it aids in achieving tumor-targeted drug delivery with micelles. It is expected that 
most sunitinib base that is encapsulated in micelles will remain in the micelle cores for a 
considerable time period when the injected micelles stay in the plasma at normal 
physiological conditions (pH 7.4); however, a faster release will occur once the micellar 
particles reach the solid tumor site where the local pH is reported to be one pH unit lower 
than that of normal tissue. In addition, micellar particles that are internalized into cells by 
endocytosis will encounter further acceleration of release inside the endosome/lysosome due 
to an additional decrease in pH [28].
The cytotoxicity of SUNb-PM against B16F10 cells was determined using an MTT assay and 
compared with sunitinib malate (Fig. 1E). The IC50 of SUNb-PM and sunitinib malate was 
5.14 and 7.78 μM, respectively. The slightly enhanced cytotoxicity of SUNb-PM could be 
attributed to the targeted binding of the particles to the sigma receptors over-expressed on 
the surface of the B16F10 cells.
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3.2. Preparation and characterization of p-Trp2 LCP vaccine
The LCP-based vaccine was prepared following the protocol we developed by our group 
[21]. As shown in Fig. 1A, the final LCP NPs containing both p-Trp2 peptide and CpG ODN 
were about 30 nm in diameter, determined by TEM after negative staining, which was 
slightly smaller than the measurement of the hydrodynamic diameter (40 – 45 nm) obtained 
by dynamic light scattering. The zeta potential was about 15 mV. The obtained vaccine was 
stored at 4 °C till use.
3.3. In vivo tumor-targeted delivery of sunitinib
We have successfully prepared SUNb-PM with high drug loading and excellent stability. To 
test whether PLGA-PEG-MBA could specifically deliver sunitinib base into tumors, in vivo 
tumor uptake studies were performed using 3H-labeled sunitinib ([3H] sunitinib) 
preparations in tumor-bearing mice. B16F10-bearing mice were administered 50 μCi/kg 3H-
labeled SUNb-PM i.v. or SUNOS p.o. As shown in Fig. 2A, SUNb-PM showed two- to four-
fold higher drug accumulation in tumors at all measured time points compared to the oral 
suspension. It can be concluded that PLGA-PEG-MBA can selectively target sunitinib base 
to tumors.
3.4. In vivo anti-tumor efficacy
To remodel the immunosuppressive tumor microenvironment, sunitinib malate is usually 
formulated as a suspension and given p.o. at a relatively high dose (20–70 mg/kg) for 7–14 
consecutive days [16, 29, 30]. Once we confirmed the excellent tumor-targeting ability of 
SUNb-PM in the above tumor accumulation study, we wondered whether a low dose of 
sunitinib base delivered using targeted PLGA-PEG-MBA micelles could boost the tumor-
specific immune response elicited by the LCP-Trp2 vaccine, thereby increasing antitumor 
efficiency.
In this study, B16F10 cells were subcutaneously inoculated in C57BL/6 mice and anticancer 
treatments were performed on tumors measuring ~200 mm3. Tumor growth inhibition was 
tested in six groups of mice receiving PBS, VAC, SUNOS (30 mg/kg, p.o.), SUNb-PM (10 
mg/kg, i.v.), V+SUNOS (30 mg/kg, p.o.), or V+SUNb-PM (10 mg/kg, i.v.). The tumor growth 
curve (Fig. 2B) shows that tumors in mice receiving VAC monotherapy elicited only partial 
tumor growth inhibition compared to the control mice that received only PBS treatment. 
This might be attributed to the strong suppressive tumor microenvironment in tumors at this 
advanced stage (14 days post tumor inoculation). Interestingly, SUNOS and SUNb-PM both 
elicited greater anti-tumor efficacy than VAC monotherapy, and even though SUNOS was 
given at a threefold higher dose, SUNb-PM showed similar antitumor efficacy. Among all 
groups, maximum tumor growth inhibition was achieved from the combination of V
+SUNb-PM. This result demonstrated that SUNb-PM could boost the tumor-specific immune 
response elicited by the Trp2 LCP vaccine, causing superior anti-tumor efficacy that was 
significantly more effective than V+SUNOS. The inhibition ratios of all formulations were 
calculated based on the tumor weight at the end of the experiment (Fig. 2C) and were 
consistent with the results from tumor volume measurements.
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The remarkable effect of V+SUNb-PM on the suppression of tumor growth is well supported 
by the histological cross-sections of the excised tumors. H&E-stained sections of tumor 
tissue from the PBS control group showed typical pathological characteristics of this tumor, 
such as closely arranged tumor cells and rich blood vessels (Fig. 2D). In contrast, the treated 
groups showed bulk necrosis and acellular regions. Among the five therapeutic groups, 
tumor tissues from the animals receiving V+SUNb-PM showed the fewest tumor cells and the 
highest antitumor efficacy. The TUNEL apoptosis assay in Fig. 2E also shows that the 
highest cellular apoptosis was generated from the V+SUNb-PM group, indicating once again 
that the best therapeutic effect resulted from this combination.
3.5. Safety evaluations
Our study was the first to intravenously administer the multikinase inhibitor sunitinib, so it 
was essential to evaluate the potential in vivo toxicity. Histological analysis of organs 
through H&E staining shows no morphological difference in major organs after treatment 
(Fig. S1), and body weight analysis of mice showed no significant weight loss or gain from 
any treatment (Fig. 3A). Hepatic and renal function was further evaluated using the serum of 
mice after treatment. The levels of biochemical parameters AST, ALT, ALKP, BUN, and 
Creatinine are shown in Fig. 3B and C. Tumor free mice were used as an additional control. 
The data shows that for all treatment groups, all parameters were in the normal range except 
AST, which was elevated in all tumor-bearing mice, consistent with reports about 
melanoma-associated toxicity [31]. After treatment, the level of AST decreased, and even 
reached the normal range in the group given V+SUNb-PM, showing that this combination 
therapy can also normalize the hepatic function of tumor-bearing mice.
3.6. The change of immune cell populations in the TME
We hypothesized that targeted SUNb-PM provided more effective tumor growth inhibition 
because its higher tumor accumulation was more effective at remodeling the 
immunosuppressive TME. To test this hypothesis, the tumors and spleens from 5 groups of 
mice were analyzed for their suppressive immune cell populations using 
immunofluorescence and flow cytometry.
In tumor-bearing hosts, myeloid-derived suppressor cells (MDSCs) and T regulator cells 
(Tregs) play important roles in immune suppression, and the reversal of their function is 
vitally important for the success of immune therapy [32]. As shown in Fig. 4B, C, E, and F, 
an increase in MDSCs and Treg cells in the tumor was observed after LCP-Trp2 vaccine 
monotherapy. The same phenomenon has also been observed for IL2-based immunotherapy 
[33]. To combat this unfavorable upregulation, we tested whether targeted delivery of 
SUNb-PM could decrease CD11b+/Gr1+ MDSC accumulation and CD4+/Foxp3+ Treg 
development in B16F10 tumor-bearing C57BL/6 mice, as the high number of MDSCs and 
Tregs in the TME might be the main reason for the undesirable anti-tumor efficacy of 
vaccine monotherapy in these advanced tumors. Treatment groups that received either a 
high-dose of SUNOS or a low dose of SUNb-PM showed a significant drop in the presence of 
intratumoral MDSCs and Tregs, and when combined with vaccine treatment, the percentage 
of MDSCs and Tregs remained as low as those of sunitinib monotherapy, indicating the 
strong ability of sunitinib to reverse the tumor’s immune suppression.
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Antitumor cytotoxic T cells, which are T cells that generally bear CD8 molecular markers 
on their surface, are of paramount importance in immune defense against tumors [34]. We 
therefore additionally measured the CD8+ T cell infiltration in the TME (Fig. 4A and D). 
The result revealed that although vaccine treatment alone resulted in a significant increase in 
CD8+ T cells, the large amount of immunosuppressive cells such as MDSCs and Tregs that 
accumulated in the TME could impair these T-cell effector functions and thus lead to poor 
tumor growth inhibition. It is interesting to note that although SUNOS alone exhibited no 
significant effect on the CD8+ T cells in the TME, SUNb-PM dramatically increased CD8+ T 
cell infiltration to levels comparable to that of the vaccine. Not surprisingly, the combination 
treatment of V+SUNb-PM yielded the highest frequencies of CD8+ T cells in the TME, 
which was as high as 18.4±2.3% (p<0.001 v.s. PBS group; p<0.05 v.s. VAC group).
The mechanisms for sunitinib to increase intra-tumor CD8 T cells while reducing intra-
tumor MDSCs and Tregs are likely complicated. According to the published papers and our 
own studies, the mechanisms for reversing immune suppressive TME might include the 
following: a) sunitinib inhibits tyrosine kinases (TK) of VEGF receptor (VEGFR), PDGFR-
α and –β, Fms-like TK-3 (Flt-3) and kit, which in turn inhibit the differentiation of dendritic 
cells (DCs) [35]; b) sunitinib enhances the frequency of myeloid DCs (mDCs), which induce 
strong killer T-cell response [36]; c) the inhibition of STAT3 and c-Kit by sunitinib might 
prevent the accumulation of MDSCs or directly induce the apoptosis of MDSCs [19, 37, 38]. 
Sunitinib treatment, alone or combined with vaccine, did not significantly change the overall 
percentage of CD11b+Gr1+ MDSC, CD4+Foxp3+Treg, or CD8+ T cells in the spleen of 
tumor-bearing mice (Fig. S3).
3.7. In vivo cytotoxic T lymphocyte assay
To further evaluate the effect of combination therapy on the activity of antigen-specific 
CD8+ killer T cells, an assay for antigen-specific CTL response was performed. In previous 
studies, we confirmed that the CTL activity elicited by the vaccine was independent of 
tumor status (early or advanced stage) [20], but the efficacy of the CTL response was 
profoundly affected by the immune microenvironment in the tumor. In the present study 
(Fig. 5), mice immunized with LCP-Trp2 were able to generate a Trp2-specific CTL 
response similar to that in a previous report [20]. Mice treated with SUNb-PM or SUNOS 
alone did not exhibit any noticeable Trp2-speific CTL response. In contrast, mice receiving 
combination therapies of V+SUNb-PM or V+SUNOS efficiently eliminated ~62.9 % and 
68.2 % of Trp2-pulsed target cells, respectively, suggesting that combination therapy elicited 
a potent Trp2-specifc in vivo CTL response compared to monotherapy. While Fig. 4 shows 
that V+SUNb-PM can reduce suppressor cells and enhance CD8+ T cell infiltration in the 
tumor, the CTL functional assay suggests that SUNb-PM can indirectly boost CD8+ T-cell 
killing efficiency by blocking the suppressor cell activity.
3.8. Cytokine expression profiles in the TME after treatment
To further understand the mechanisms underlying the reversion of immune suppression 
mediated by SUNb-PM, we investigated the change in the cytokine expression profiles in the 
TME after treatment. Cytokines are important protein mediators of the immune response. 
The cytokine content of the microenvironment can influence the balance of 
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immunosuppressive and immunosupportive factors within tumors [39]. The pro le of 
cytokines expressed by T cells during an immune response can be broadly categorized into 
two polarized groups, T helper 1 (Th1) and T helper 2 (Th2), which activate cell-mediated or 
humoral immunity, respectively. A Th1 response is typified by the expression of IFNγ, IL2, 
and IL12a, while Th2 responses are typified by CCL2, IL6, IL10, TGFβ, and TNFα 
expression. Previous studies suggest that a Th1 response is more effective in eliciting anti-
tumor immunity and that Th2 cytokines inhibit the development of anti-tumor immunity 
[40]. A gradual loss in Th1 and increase in Th2 cytokine profiles has been observed during 
progressive tumor growth [41].
The cytokine expression after treatment is shown in Fig. 6. Treatment with sunitinib alone or 
combined with VAC resulted in a polarization of the immune response toward the cellular 
immune pathway promoting Th1 cytokine expression and reducing Th2 cytokine expression. 
The shift from Th2 to Th1 provides regulatory signals required for the priming of MHC 
class I-restricted CD8+ CTLs, and the activated CTLs serve predominantly as immune 
effectors that induce apoptotic tumor cell death. Although IL12a, a Th1-type cytokine, 
exhibits a contrary tendency, it does not change the overall trend of cytokine transformation. 
It is also noteworthy that the Trp2-specific vaccine significantly increased the expression of 
IL10 in the TME, while exhibiting no significant effect on other Th2-type cytokines. The 
high level of IL10 might be responsible for the poor therapeutic effect of VAC treatment 
alone; however, after combined treatment with SUNOS or SUNb-PM, the level of IL10 
significantly decreased.
Sunitinib treatment inducing a shift from a type 2-cytokine response to a type 1 response in 
the tumor has been reported many times in the literature [19, 42, 43], but the precise 
mechanism is not clear. Finke’s study suggested that the increased type-1 response after the 
therapy may be partly attributable to a reduction in the elevated number of Treg cells and is 
independent of either tumor shrinkage or objective clinical responses in renal cell carcinoma 
(RCC) patients [44]. The reduction in Tregs cells could be an indirect effect because 
sunitinib did not alter the expansion of either Treg cells or T-effector cells. The changes in 
Treg cells is likely related to the fact that sunitinib decreases the expression of MDSC cells 
[44, 45]. Our study also showed that SUNb-PM could decrease the number of Tregs and 
MDSCs in the advanced melanoma model. Agreeing with Finke, the improved type-1 
cytokine response along with a reduction in the type-2 cytokines following sunitinib 
treatment may also be linked to the reduction of Treg cells. Moreover, we also found that 
sunitinib therapy not only changed the immune cell populations, but also altered the tumor 
structure such as tumor-associated fibroblasts, collagen, blood vessels as well as the 
permeability of the tumor (Section 3.9). The favorable remodeling of TME might work 
together to promote cytokine shift from Th2 to Th1 polarization. Further studies are needed 
to clarify the mechanism of action of sunitinib in the advanced melanoma.
3.9. Structural changes in the TME: vasculature, tumor associated fibroblasts (TAF), 
collagen fibers, and tumor permeability
The hypoxic tumor environment results in an abnormal blood vessel network that allows 
metastatic tumor cells to escape and strongly prevents infiltration of anti-cancer treatments 
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into the tumor mass [46]. Restoration of the abnormal tumor vessel phenotype to normalized 
vasculature can restore a proper immune response in the TME. We therefore examined the 
vessel content and distribution as well as the morphological changes in the tumor by 
measuring areas positive for the blood vessel marker CD31 using immunofluorescence 
staining. As shown in Fig. 7A, vessels stained with red fluorescence were abundant and 
randomly distributed in the untreated tumor. Moreover, the vessels in the untreated group 
were thin and elongated due to the high pressure in the TME (white arrows in Fig. 7A), 
which can greatly impede the infiltration of contents from vessels. VAC alone significantly 
reduced the vessel concentration, consistent with the previous report that immunotherapies 
can reduce tumor vasculature through release of IFNI and II in the TME [13]; however, the 
vessels were still crushed under the high pressure in the TME. SUNOS and SUNb-PM 
monotherapy exhibited an even stronger antiangiogenic effect, inhibiting angiogenesis likely 
by blocking the phosphorylation of VEGFRs, PDGFRs, and other receptors on the cell 
membrane of tumor endothelial cells [29]. Interestingly, the remaining vessels in sunitinib-
treated groups exhibited a round and open morphology (white arrowheads in Fig. 7A), an 
effect that was more pronounced in the SUNb-PM group. The normalization of the tumor 
vasculature in response to treatment, as well as the apoptotic decrease in cell and collagen 
density, can significantly decrease the interstitial pressure in the TME, which may enhance 
the infiltration of lymphocytes and/or nanoparticles into the tumor [47]. To confirm this 
increase in tumor permeability, we measured the accumulation of DiI fluorescence in tumors 
using Dil-labeled PLGA-PEG-MBA PMs (Fig. 7A, green). The PBS group exhibited poor 
tumor permeability and only weak fluorescence was observed, but combined treatment with 
V+SUNb-PM elicited the strongest and most widespread fluorescence, indicating that the 
combination therapy induced the highest permeability of the tumor. The enhanced 
permeability of the tumor tissue also likely favored the infiltration of lymphocytes into the 
tumors [48], in addition to possibly increasing the drug accumulation in the tumor upon 
subsequent dosing.
In the TME, TAFs aid the tumor in immune modulation by impeding antitumor T cell 
function [49]. Therefore, the effect of VAC and SUN on TAFs was also investigated by 
staining for α-smooth muscle actin (α-SMA), a marker for TAFs. The α-SMA staining 
showed that VAC alone partially attenuated the amount of α-SMA-positive cells, while V
+SUNb-PM almost completely eliminated the fibroblast population in the tumor tissue (Fig. 
7B), indicating that the combination not only affected tumor cells, but also depleted TAFs.
The over-expressed collagens in tumors not only create a microenvironment that supports 
tumor cell survival and enhances cell migration, but they also act as ligands for the 
inhibitory receptor LAIR-1, which inhibits the function of multiple types of immune cells 
[50]. Thus, we used Masson’s Trichrome staining to study the collagen content and the 
morphology of the treated tumors (Fig. 7C). B16F10 melanoma does not develop an 
extensive stromal structure compared to other solid tumors [51, 52], so stroma revealed by 
the collagen staining showed thin and elongated fibrous structures in the PBS-treated tumor 
(blue staining indicated by yellow arrows in Fig. 7C). V+SUNb-PM again showed the 
greatest collagen inhibition compared to the other treatment groups. Taken together, these 
data indicate that V+SUNb-PM elicited a significant change in the structural tumor 
microenvironment.
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3.10. Signaling pathway determinations
Because sunitinib is a known tyrosine kinase inhibitor, we examined several major 
downstream signaling molecules of tyrosine kinases, including AKT and Stat3. The results 
show that VAC monotherapy significantly increased the p-Stat3 protein levels compared to 
the PBS-treated group (p<0.001). However, when the tumor-bearing mice were treated with 
V+SUNb-PM, a significant decrease in the p-Stat3 level in the tumors was observed (Fig. 8). 
Stat3 is constitutively activated in diverse cancer cell types, including melanoma. Frequent 
Stat3 activation in tumor cells is largely due to Stat3 being a point of convergence for 
numerous tyrosine kinases, including VEGFR, PDGFR, EGFR, and Src [37]. The inhibition 
of p-Stat3 in tumor cells can inhibit tumor growth by inducing tumor cell apoptosis [53], 
which we show in Fig. 1 and 3. Stat3 is also activated in many types of tumor-associated 
immune cells, including myeloid cells, promoting tumor immune evasion as well as tumor 
angiogenesis [54]. Ablating Stat3 in tumor myeloid cells can increase dendritic cell 
activation, tumor Treg reduction, and CD8+ T-cell activation [55]. Moreover, it was recently 
documented that Stat3 was critically involved in tumor accumulation of MDSCs, which play 
an important role in suppressing antitumor immune responses [56]. This literature suggests 
that the decreased p-Stat3 expression induced by sunitinib might be responsible for the 
change in the TME. We also measured a decrease in p-AKT expression as a result of V
+SUNb-PM, which could also have a profound effect on tumor growth and progression [57].
4. Conclusions
In this report, we found that tumor-targeted delivery of a low dose of sunitinib base in 
PLGA-PEG-MBA micelles decreased the number and percentage of MDSCs and Tregs in 
the TME, increased cytotoxic T cell infiltration, and changed the cytokine profiles and 
stromal structure of the tumor, thereby abrogating tumor-associated immune suppression and 
working synergistically with our vaccine therapy in advanced B16F10 melanoma tumor-
bearing mice. Our studies provide evidence in an in vivo animal model that targeted delivery 
of tyrosine kinase inhibitors to tumors can be used in a novel synergistic way to enhance the 
therapeutic efficacy of existing immune-based therapies for advanced tumors.
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Abbreviations
LCP lipid calcium phosphate
NP nanoparticles
Trp2 tyrosinase-related protein 2 (Trp2)
TME tumor microenvironment
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PM polymeric micelle
PLGA-PEG-MBA anisamide modified poly-lactic-glycolic-acid-poly(ethylene 
glycol) (PLGA-PEG-MBA)
SUNb-PM sunitinib base-loaded polymeric micelles
SUNos sunitinib malmate oral suspension
TKI tyrosine kinase inhibitor
VEGF vascular endothelial growth factor
CTL cytotoxic T lymphocyte
DPTAP 1,2-Dioleoyl-3-trimethylammonium-propane chloride salt
DSPE-PEG 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethyleneglycol-2000)] ammonium salt
DOPA dioleoylphosphatydic acid
TEM transmission electron microscopy
CMC carboxymethylcellulose
IR inhibition ratio
H&E staining hematoxylin and eosin staining
TUNEL terminal deoxynucleotidyl transferase-mediated nick end 
labeling
ALT alanine transaminase
AST aspartate transaminase
ALP alkaline phosphatase
BUN blood urea nitrogen
Scr serum creatinine
RBCs red blood cells
BSA bovine serum albumin
TAF tumor associated fibroblast
DiI 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine 
perchlorate
HRP horseradish peroxidase
MDSC myeloid-derived suppressor cells
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Treg T regulator cells
Th1 T helper 1
Th2 T helper2
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Fig. 1. 
TEM images of (A) p-Trp2 LCP vaccine and (B) SUNb-PM after negative staining. (C) In 
vitro stability of SUNb-PM at 4°C. (D) In vitro release of sunitinib base from PLGA-PEG 
micelles at pH 5.8 and pH 7.4. (E) Cytotoxicity of SUNOS and SUNb-PM against B16F10 
cells after 24 h. The error bars in the graphs represent standard derivations (n=3).
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Fig. 2. 
(A) Tumor accumulation of 3H-labeled SUNb-PM and SUNOS in C57BL/6 mice bearing 
B16F10 tumors at t = 3, 6, 12 and 24 h after treatment. The dose of 3H-labeled drug was 50 
μCi/kg. (B–E) Antitumor activity of PBS, VAC, SUNOS, SUNb-PM, V+SUNOS and V
+SUNb-PM on B16F10 tumor-bearing mice. C57BL/6 mice were inoculated with 2×105 
B16F10 cells on day 0. VAC was injected on day 14 at a dose of 0.3 mg/kg; SUNOS was 
given p.o. or SUNb-PM was given i.v. on days 14, 16, and 18 at a dose of 30 mg/kg or 10 
mg/kg, respectively. Tumor growth was measured every day until the 19th day after 
inoculation. Mice were sacrificed on day 19 and tumors were harvested. (B) Tumor volumes 
of tumor-bearing mice as a function of time. The arrows (pink for VAC and blue for SUN) 
indicate the time points of drug administration. (C) Tumor inhibition ratio calculated based 
on the weight of tumor at the end of the tests. (D) H&E staining of tumor sections. The 
white scale bar represents 100 μm. (E) TUNEL-positive cells in tumor sections excised from 
the mice seven days after the first treatment. The yellow scale bar represents 50 μm. Three 
randomly selected microscopic fields were quantitatively analyzed using ImageJ. The results 
are displayed as mean ± S.D. (error bars). Statistical analyses were calculated by comparing 
with the untreated group, unless otherwise specified. *p < 0.05, **p < 0.01, ***p< 0.001, n 
= 5.
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Fig. 3. 
Safety evaluations. (A) Body weight change of B16F10-bearing mice after treatment with 
VAC, SUNOS, SUNb-PM, V+SUNOS, or V+SUNb-PM. (B) Liver and (C) kidney function 
assays after treatment. Results were expressed as the mean ± S.D. (n = 5). The normal 
ranges for all the biochemical parameters are shown in the upper right corner of panels B 
and C.
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Fig. 4. 
Tumor infiltrating immune cells after treatment. C57BL/6 mice were inoculated with 2×105 
B16F10 cells on day 0. VAC was injected on day 14 at a dose of 0.3 mg/kg; SUNOS and 
SUNb-PM were p.o. or i.v. administered on days 14, 16, and 18 at a dose of 30 mg/kg or 10 
mg/kg, respectively. Mice were sacrificed on day 19 and tumors were harvested. Tumor 
tissues were assayed for CD8+ T cells, CD11b+/Gr1+ MDSC cells, and Foxp3+/CD4+ Treg 
cells with immunofluorescence staining, and representative immunofluorescence images 
were presented (A-C). Flow cytometric analysis was also used to quantify immune cells in 
the TME (D-F). The results are displayed as mean ± S.D. (error bars). Statistical analyses 
were calculated by comparing to the untreated group unless otherwise specified with 
markings. *p < 0.05, **p < 0.01, ***p< 0.001, n = 3.
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Fig. 5. 
In vivo CTL response after vaccination under various conditions. C57BL/6 mice were 
subcutaneously injected with VAC on day 1, and treated with SUNOS or SUNb-PM on days 1, 
3 and 5. Splenocytes from naive mice were pulsed with Ova or Trp2 peptide and stained 
with low (Ova) or high (Trp2) concentrations of CFSE, respectively. The cells were then 
mixed and injected i.v. into the vaccinated mice. After 18 h, splenocytes from the vaccinated 
mice were analyzed by flow cytometry and enumerated according to a published equation 
[20]. A representative graph from each group is shown. *p < 0.05, **p < 0.01, ***p< 0.001, 
n = 3.
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Fig. 6. 
Tumor cytokine levels after vaccination. C57BL/6 mice were inoculated with 2×105 B16F10 
cells on day 0. VAC was given on day 14 and SUN treatments were given on days 14, 16, 
and 18. Mice were sacrificed on day 18, and tumors were collected for cytokine detection 
using RT-PCR. The results are displayed as mean ± S.D. (error bars). Statistical analyses 
were calculated by comparison with the untreated group. *p < 0.05, **p < 0.01, *** p< 
0.001, n = 5.
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Fig. 7. 
(A) Vessels in B16F10 tumors stained with CD31 antibody (red) to measure vasculature and 
DiI-labeled PLGA-PEG micelles (false color green) to measure tumor permeability. 
C57BL/6 mice were inoculated with 2×105 B16F10 cells on day 0. VAC was injected on day 
14 at a dose of 0.3 mg/kg; SUNOS and SUNb-PM were p.o. or i.v. administered on days 14, 
16 and 18 at a dose of 30 mg/kg and 10 mg/kg, respectively. On day 19, the mice were i.v. 
injected with DiI-loaded PLGA-PEG micelles. Twenty four h after injection, the mice were 
sacrificed and tumors were harvested. The blood vessels were stained using an anti CD31 
antibody; the cell nucleus was stained using DAPI (blue); the PLGA NPs were labeled with 
DiI. The white scale bar represents 100 μm. The white arrows indicate the thin and 
elongated vessels; the white arrowheads indicate the round and open vessels. (B) TAFs in 
tumors stained with α-SMA antibody (red), scale bar = 50 μm; (C) tumor sections stained 
with Masson’s Trichrome, scale bar = 50 μm. The tumor-bearing mice in (B) and (C) were 
treated according to the above schedule and sacrificed on day 19. In (C), the blue color 
represents collagen fibers (yellow arrows). To quantify the fields, three randomly selected 
microscopic fields were quantitatively analyzed using ImageJ (D, E, F). The results are 
displayed as mean ± S.D. (error bars). Statistical analyses were calculated by comparing to 
the untreated group unless otherwise specified. *p<0.05,**p < 0.01, ***p< 0.001, n = 3.
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Fig. 8. 
Expression levels of p-Stat3, Stat3, p-AKT, AKT, and GAPDH in tumor samples after 
treatment. C57BL/6 mice were inoculated with 2×105 B16F10 cells on day 0. VAC was 
injected on day 14 at a dose of 0.3 mg/kg; SUNOS and SUNb-PM were administered p.o. or 
i.v. on days 14, 16, and 18 at a dose of 30 mg/kg and 10 mg/kg, respectively. Mice were 
sacrificed on day 19 and tumors were collected for western blot analysis. The results are 
displayed as mean ± S.D. (error bars). Statistical analyses were calculated by comparing 
with the untreated group unless specified with markings. *p < 0.05, **p< 0.01, ***p < 
0.001, n = 5.
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Scheme 1. 
Schematic illustration of SUNb-PM and LCP-Trp2 vaccine injected into the advanced 
melanoma-bearing mouse.
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